There is no single routine doctor’s-office test that definitively diagnoses insulin resistance. Clinicians usually check risk factors, symptoms, waist size, blood pressure, A1C, fasting glucose, lipid levels, and sometimes fasting insulin or HOMA-IR. Prediabetes and diabetes tests are often the practical starting point for finding insulin-related metabolic risk 1.
Wondering if GLP-1 is right for you? Take the 3-min clinical quiz.
See if you qualify →How do you check insulin resistance?
Insulin resistance is usually checked by looking for a pattern, not by relying on one perfect test. A clinician may review your history, waist size, blood pressure, skin findings, A1C, fasting glucose, lipids, and sometimes fasting insulin or HOMA-IR over several months of follow-up 1, 2.
Quick facts: the most useful things to know before you test
- A normal A1C does not always rule out early insulin resistance because the body may still be keeping glucose in range.
- A fasting glucose test is useful, but it only shows one point in time.
- An oral glucose tolerance test can show how your body handles a glucose load over time 1.
- Fasting insulin and HOMA-IR can give extra context, but there is no single universal cutoff for everyone 2.
- Insulin resistance cannot be confirmed or ruled out from symptoms alone.
Why insulin resistance can exist before blood sugar becomes high
Early on, the pancreas can respond to insulin resistance by making more insulin. This is called hyperinsulinemia. Blood glucose may stay normal for a while, even though the body is working harder to keep it there 3.
Why a clinician may look for patterns instead of relying on one test
Insulin resistance affects more than glucose. It is linked with high blood pressure, higher triglycerides, lower HDL cholesterol, fatty liver disease, metabolic syndrome, prediabetes, and type 2 diabetes risk 1, 3. That is why the full pattern often matters more than one lab value.
What is insulin resistance?
Insulin resistance means the body’s tissues do not respond normally to insulin, especially muscle, liver, and fat tissue. Over time, this can raise insulin levels, increase glucose levels, and add stress to metabolic health 1, 3.
How insulin normally helps move glucose into cells
Insulin is a hormone made by the pancreas. After you eat, insulin helps move glucose from the blood into cells, where it can be used or stored for energy 1.
What happens in muscle, liver, and fat tissue when insulin response is reduced
When insulin sensitivity is reduced, muscle may take up less glucose, the liver may keep releasing glucose when it should slow down, and fat tissue may send signals that worsen inflammation and metabolic stress 3, 4.
How insulin resistance relates to prediabetes and type 2 diabetes
Prediabetes is diagnosed when blood glucose is above normal but not high enough for type 2 diabetes. Insulin resistance can raise the chance of prediabetes and type 2 diabetes, but not everyone with insulin resistance has diabetes 1.
What warning signs can point to insulin resistance?
Warning signs can include a larger waist size, weight gain, high blood pressure, high triglycerides, low HDL cholesterol, skin darkening, PCOS, fatty liver disease, sleep apnea, and family history. Many people have no symptoms, so testing and clinical context matter 1.
Common clues: larger waist size, weight gain, high blood pressure, high triglycerides, and low HDL
- Larger waist size or weight gain, especially around the abdomen
- High blood pressure or a new diagnosis of hypertension
- High triglycerides or low HDL cholesterol on a lipid panel
- Prediabetes-range A1C, fasting glucose, or oral glucose tolerance test
- Metabolic syndrome or fatty liver disease
Skin changes such as acanthosis nigricans
Acanthosis nigricans is darker, thicker, velvety skin that often appears around the neck, armpits, or skin folds. It can be seen with insulin resistance, but it has other causes too, so it should be checked by a clinician 1.
PCOS, fatty liver, sleep apnea, and family history as risk signals
Polycystic ovary syndrome, also called PCOS, is linked with insulin resistance in many patients. Fatty liver disease, now often called metabolic dysfunction-associated steatotic liver disease, sleep apnea, gestational diabetes history, and a family history of type 2 diabetes can also raise risk 1, 3. If PCOS is part of your picture, our guide to PCOS symptoms and treatment options may help you prepare for a visit.
Why many people have no symptoms
Insulin resistance and prediabetes can be quiet. NIDDK notes that people with insulin resistance and prediabetes often do not have symptoms, which is why risk-based screening is important 1. You can also read our deeper guide to signs of insulin resistance.
What blood tests help screen for insulin resistance risk?
Blood tests do not all measure insulin resistance directly. In routine care, clinicians often start with A1C, fasting blood glucose, an oral glucose tolerance test when needed, and lipids; fasting insulin or HOMA-IR may be added when it fits the clinical question 1, 2.
| Test | What it tells you | Strengths | Limits |
|---|---|---|---|
| A1C | Average blood glucose over about 2 to 3 months | Common, convenient, useful for prediabetes and diabetes screening | Can miss early insulin resistance and may be affected by some blood conditions |
| Fasting blood glucose | Blood glucose after fasting | Simple first-line screen | One point in time; may be normal early |
| Oral glucose tolerance test | Glucose response after a measured glucose drink | Can find impaired glucose tolerance that fasting glucose may miss | Takes longer and is less convenient |
| Fasting insulin | How much insulin is present while fasting | Can suggest compensation when glucose is still normal | Assays and reference ranges vary |
| HOMA-IR or HOMA2 | Calculated estimate using fasting glucose and insulin | Used often in research and some clinical settings | No single universal cutoff |
| Lipid panel | Triglycerides, HDL, LDL, and total cholesterol | Helps show cardiometabolic risk pattern | Does not diagnose insulin resistance alone |
| Liver enzymes | Possible liver stress or fatty liver clues | May guide further evaluation | Can be normal even with fatty liver |
A1C
A1C is often used to screen for prediabetes and diabetes because it reflects average blood glucose over about 2 to 3 months. It does not directly measure insulin levels or insulin sensitivity 1. For more detail, see our A1C blood sugar test guide.
Fasting blood glucose
Fasting blood glucose measures blood sugar after not eating for a set period. It is practical and common, but early insulin resistance can exist while fasting glucose is still in range 1. Our guide to normal fasting blood sugar explains how clinicians usually interpret results.
Oral glucose tolerance test
An oral glucose tolerance test checks blood glucose before and after a measured glucose drink. It can show impaired glucose handling that may not appear on fasting glucose alone 1.
Fasting insulin and HOMA-IR
Fasting insulin may show that the pancreas is making extra insulin to keep glucose normal. HOMA-IR is a calculation based on fasting insulin and fasting glucose, but interpretation depends on the lab, population, and clinical setting 2, 3.
Lipid panel, including triglycerides and HDL
High triglycerides and low HDL cholesterol can fit an insulin resistance pattern. Researchers and clinicians also discuss the triglyceride-to-HDL ratio as a surrogate marker, but it is not a stand-alone diagnosis 3.
Liver enzymes and other tests a clinician may consider
A clinician may check liver enzymes, kidney function, thyroid testing, medication effects, pregnancy history, or PCOS-related labs depending on your situation. Fatty liver disease and insulin resistance often overlap, but liver enzymes alone do not rule it in or out 3.
Which insulin resistance tests are research tools versus routine care?
Research tests can measure insulin resistance more directly, but they are not usually practical in everyday care. The hyperinsulinemic-euglycemic clamp is often called the gold standard, while HOMA-IR, QUICKI, triglycerides, and triglyceride-to-HDL ratio are surrogate markers 2, 3.
Hyperinsulinemic-euglycemic clamp: the research gold standard
The hyperinsulinemic-euglycemic clamp measures how much glucose is needed to keep blood sugar steady while insulin is infused. It gives a direct view of insulin sensitivity, but it is complex and time-intensive 2.
Why clamp testing is rarely used in routine clinical care
Clamp testing requires specialized staff, equipment, time, and careful monitoring. For most patients, clinicians use practical office-based screening to estimate risk and guide next steps 2.
How surrogate markers such as HOMA-IR, QUICKI, triglycerides, and triglyceride-to-HDL ratio are used
Surrogate markers estimate insulin resistance from easier-to-collect labs. They can be useful for patterns and research, but each has limits, and results should be interpreted with the full health picture 2, 3.
Can you be insulin resistant and not diabetic?
Yes. Insulin resistance can be present while A1C and fasting glucose are still normal, especially early on. The pancreas may make extra insulin for years before blood glucose rises into the prediabetes or type 2 diabetes range 1, 3.
Why blood sugar may stay normal early on
If the pancreas can make enough extra insulin, glucose may stay in range. This can hide the problem if only glucose is checked once 3.
How the pancreas can compensate by making more insulin
This compensation is called hyperinsulinemia. In a nondiabetic study population, insulin resistance and insulin response were strongly linked, showing how higher insulin output often travels with reduced insulin sensitivity 5.
When insulin resistance may progress toward prediabetes or type 2 diabetes
If the pancreas can no longer keep up, blood glucose may rise. NIDDK states that prediabetes can progress to type 2 diabetes if blood glucose keeps going up 1.
What should you ask your clinician if you suspect insulin resistance?
A clinician visit should connect your risk factors with the right labs. Ask which tests make sense based on your age, weight history, waist size, blood pressure, family history, PCOS, pregnancy history, medications, and symptoms; retesting may happen over months depending on results 1.
Which labs are reasonable based on age, weight, family history, PCOS, pregnancy history, and medications
- Should I check A1C, fasting glucose, or an oral glucose tolerance test?
- Would fasting insulin or HOMA-IR add useful context for me?
- Do my triglycerides, HDL cholesterol, blood pressure, or waist size suggest metabolic syndrome?
- Should we check liver enzymes or evaluate for fatty liver disease?
- Could any of my medications affect glucose, weight, or insulin sensitivity?
How often to retest if results are normal or show prediabetes
Retesting depends on your baseline results and risk. If results are normal but risk is high, your clinician may choose periodic monitoring; if results show prediabetes, follow-up is usually more structured 1.
When symptoms need urgent medical attention
Get urgent care for symptoms of very high blood sugar such as severe thirst, frequent urination with dehydration, vomiting, confusion, fruity-smelling breath, trouble breathing, or severe weakness. These symptoms can signal a serious problem and should not wait for a routine appointment 6.
What helps insulin resistance improve?
Lifestyle modification is the first-line focus for insulin resistance care. Evidence supports weight management when relevant, physical activity, strength training, nutrition changes, sleep support, smoking cessation, and medication review; changes are usually tracked over weeks to months, not days 1, 3.
Weight management and waist reduction when relevant
For people with excess weight or larger waist size, weight loss and waist reduction can improve insulin sensitivity and cardiometabolic risk markers. Individual results vary, and weight is only one part of the picture 1, 3. Our guide to losing weight with insulin resistance covers this in more detail.
Physical activity and strength training
Physical activity helps muscles use glucose and improves skeletal muscle insulin sensitivity. Strength training can also help preserve or build lean tissue, which matters because muscle is a major glucose-handling organ 3.
Mediterranean-style eating patterns and carbohydrate quality
A Mediterranean-style pattern usually emphasizes vegetables, beans, lentils, whole grains, nuts, olive oil, fish, and minimally processed foods. Carbohydrate quality matters: fiber-rich foods tend to have a different metabolic effect than refined starches and sugary drinks 7.
Sleep, smoking cessation, and medication review
Sleep apnea, poor sleep, smoking exposure, and some medications can worsen metabolic risk. NIDDK lists sleep apnea, smoking, and certain medicines among risk factors linked with insulin resistance and prediabetes 1.
When prescription medication may fit
Medication may be considered when lifestyle steps are not enough, when prediabetes or type 2 diabetes risk is high, or when weight-related health risk is present. Metformin has long been used in diabetes prevention and insulin resistance contexts, while GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists are prescribed in weight-management care for eligible patients; benefits must be weighed against side effects and contraindications 8, 9, 10.
| Your situation | Reasonable next step | Why it may fit | Trade-offs |
|---|---|---|---|
| Normal A1C but strong risk factors | Ask about fasting glucose, lipids, blood pressure, waist size, and whether fasting insulin adds value | Early insulin resistance may exist before glucose rises | No single test can confirm everything |
| Prediabetes-range labs | Build a structured plan for food, activity, weight, sleep, and follow-up labs | Prediabetes is a warning point where prevention work matters | Change takes time and repeat testing |
| PCOS plus weight or glucose concerns | Ask about metabolic labs and PCOS-focused care | PCOS is linked with insulin resistance in many patients | Treatment depends on cycle goals, pregnancy goals, and symptoms |
| Excess weight with metabolic risk | Discuss weight-management care, including whether medication is appropriate | Weight loss can improve insulin sensitivity for some people | Medication has side effects and is not right for everyone |
| Urgent high-blood-sugar symptoms | Seek urgent medical care | Severe symptoms may signal dangerous hyperglycemia | Do not wait for routine testing |
3-min quiz
Want a clinician-reviewed weight-loss plan?
If weight-related metabolic risk is part of your insulin resistance picture, Chia can help you start with an online eligibility review. We offer compounded semaglutide injection and compounded tirzepatide tablets or injection for eligible patients. A licensed provider reviews your health history and prescribes only when clinically appropriate; a prescription is not guaranteed. Compounded drugs are not FDA-approved.
Insulin resistance, weight loss, and treatment options at Chia
Chia evaluates weight-related metabolic risk through a 100% online clinician review. For eligible patients seeking weight-loss care, our providers may consider compounded semaglutide injection or compounded tirzepatide tablets or injection, with provider-guided dosing and microdosing plans available where clinically appropriate.
How Chia evaluates weight-related metabolic risk through an online clinician review
At Chia, you start with a short health questionnaire. A licensed US provider reviews your medical history, current medications, goals, contraindications, and labs when needed before deciding whether treatment is appropriate.
When GLP-1 treatment may be considered for eligible patients seeking weight-loss care
Semaglutide, known by brand names such as Ozempic and Wegovy, is a GLP-1 receptor agonist. Tirzepatide, known by brand names such as Mounjaro and Zepbound, is a dual GIP/GLP-1 receptor agonist. These medicines can be part of weight-management care for eligible patients, but they do not diagnose insulin resistance and are not right for everyone 9, 10.
Semaglutide at Chia: compounded injection with provider-guided dosing and microdosing plans available
Chia offers compounded semaglutide injection, with plans currently starting at $249/mo. Dosing is provider-guided and adjusted over time; microdosing plans are available when clinically appropriate. Common side effects of semaglutide as studied include nausea, vomiting, diarrhea, constipation, and abdominal pain, and it has important contraindications and warnings that a clinician must review 9.
Tirzepatide at Chia: compounded tablets or injection with provider-guided dosing and microdosing plans available
Chia offers compounded tirzepatide tablets or injection. Plans currently start at $249/mo for tablets and $299/mo for injection. Dosing is provider-guided and adjusted over time; microdosing plans are available when clinically appropriate. Common side effects of tirzepatide as studied include nausea, diarrhea, vomiting, constipation, abdominal pain, and dyspepsia, and a clinician must review warnings and contraindications 10.
| Chia option | Forms Chia offers | Current starting price | Best fit to discuss |
|---|---|---|---|
| Semaglutide | Injection | From $249/mo | Patients who prefer a provider-guided injectable GLP-1 option |
| Tirzepatide | Tablets or injection | From $249/mo tablets; from $299/mo injection | Patients who want to discuss tablet versus injection options with a provider |
| Weight + Energy | NAD+ injection plus choice of GLP-1 | From $309/mo | Patients who want weight-loss care plus an energy-focused longevity protocol |
| Weight + Muscle | Sermorelin injection plus choice of GLP-1 | From $329/mo | Patients who want weight-loss care plus a muscle-focused protocol |
Some patients ask about combined protocols. Chia’s Weight + Energy protocol includes NAD+ injection plus a choice of GLP-1, and Weight + Muscle includes Sermorelin injection plus a choice of GLP-1. These still require a clinician review, and they are not a shortcut around nutrition, movement, sleep, or lab follow-up.
When Chia may not be the right fit and why a prescription is never guaranteed
Chia may not be the right fit if your symptoms suggest urgent diabetes care, if you need in-person evaluation, if you are pregnant, or if a medication is unsafe based on your history. Prescriptions are issued only when clinically appropriate and are never guaranteed.
If you use an AI agent to help organize your care, Chia can also be reached through DoctorMCP at mcp.chia.health for supported prescription-delivery workflows. The clinical review still happens with a licensed provider.
How should you track progress over time?
Progress tracking works best when you follow trends, not one isolated number. A clinician may repeat A1C, fasting glucose, lipids, blood pressure, waist size, and selected markers over 3 to 12 months, depending on your starting point and risk 1.
Repeat labs: A1C, fasting glucose, lipids, and clinician-selected markers
Repeat testing helps show whether your plan is moving glucose and cardiometabolic markers in the right direction. A1C, fasting glucose, triglycerides, HDL cholesterol, and liver enzymes may be followed when relevant 1, 3.
At-home tracking: weight, waist, activity, blood pressure, and symptoms
At home, useful trends can include weight, waist size, activity minutes, strength training, sleep, blood pressure, and symptoms. These do not replace labs, but they help your clinician see the whole pattern.
Why trends matter more than one isolated number
Hydration, stress, sleep, illness, and recent meals can affect some numbers. A trend across labs and home measures is usually more useful than one result by itself.
When should you get medical help now?
Get help now if you have severe thirst, frequent urination with dehydration, vomiting, confusion, trouble breathing, severe weakness, chest pain, fainting, or symptoms of very high blood sugar. These are not symptoms to track for weeks at home 6.
3-min quiz
Start with an online eligibility review
If your main goal is weight-loss care and metabolic risk reduction, you can begin with Chia’s online review. A licensed provider will decide whether compounded semaglutide, compounded tirzepatide, a protocol, or no prescription is appropriate for you. Prescriptions are not guaranteed, and compounded medications are not FDA-approved.
The hyperinsulinemic-euglycemic clamp is the research gold standard, but it is rarely used in routine care. Most clinicians use practical screening: A1C, fasting glucose, lipids, blood pressure, waist size, risk factors, and sometimes fasting insulin or HOMA-IR.
Yes. A1C reflects average blood glucose, not insulin levels. Early insulin resistance can exist while the pancreas is still making enough extra insulin to keep blood sugar in range.
It can be useful in context, especially when glucose is normal but insulin resistance is suspected. The limit is that insulin assays and reference ranges vary, so the result should be interpreted by a clinician.
There is no single universal HOMA-IR cutoff that applies to everyone. Cutoffs vary by lab method, population, age, and health context. Ask your clinician how your lab defines and interprets the result.
Insulin sensitivity can improve for many people with weight management when relevant, regular activity, strength training, nutrition changes, sleep support, and treatment of related conditions. The amount of improvement varies.
It depends on your risk factors and results. If you have prediabetes, PCOS, fatty liver disease, strong family history, or weight-related metabolic risk, your clinician may recommend more regular monitoring than someone at low risk.
No. Weight loss can improve insulin sensitivity for many people with excess weight, but it does not always fix the full issue. Genetics, sleep, medications, PCOS, fatty liver disease, activity level, and age can also matter.
GLP-1 and GIP/GLP-1 medications may be considered in weight-management care for eligible patients with weight-related metabolic risk. They are not a diagnostic test for insulin resistance. Compounded formulations are not FDA-approved and do not have FDA-evaluated outcomes data.
References
- 1.National Institute of Diabetes and Digestive and Kidney Diseases. Insulin Resistance & Prediabetes. NIDDK, 2024.
- 2.Muniyappa R, Lee S, Chen H, Quon MJ. Measuring Insulin Resistance in Humans. American Journal of Physiology-Endocrinology and Metabolism, 2021.
- 3.Freeman AM, Pennings N. Insulin Resistance. StatPearls. NCBI Bookshelf, 2024.
- 4.Alzahrani SH, Baig M, Aashi MM, Al-Shaibi FK, Alqarni DA, Bakhamees WH. Mapping the landscape of research on insulin resistance. Diabetology & Metabolic Syndrome, 2024.
- 5.Kim SH, Reaven GM. Insulin Resistance and Hyperinsulinemia. Diabetes Care, 2008.
- 6.Centers for Disease Control and Prevention. Diabetic Ketoacidosis. CDC, 2024.
- 7.Armin M, Heidari Z, Askari G, et al. The effect of a low renal acid load diet on blood pressure, lipid profile, and blood glucose indices in patients with type 2 diabetes: a randomized clinical trial. Nutrition Journal, 2023.
- 8.Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine, 2002.
- 9.U.S. Food and Drug Administration. Wegovy (semaglutide) prescribing information. FDA, 2024.
- 10.U.S. Food and Drug Administration. Zepbound (tirzepatide) prescribing information. FDA, 2025.
About this article
Chia Health Editorial Team — Evidence-reviewed health education
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
AI tools may assist with research and drafting. Chia's editorial team reviews source use, clarity, treatment information, and safety framing before publication. A clinician is named only after explicit sign-off. Read our editorial standards.
Get a personalized plan
See if GLP-1 is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
